Fighting tuberculosis: Breakthrough analysis reveals mixed strain infections

Vaxart an­nounced on Wednes­day that a Phase II study of its oral norovirus vac­cine achieved the pri­ma­ry end­point of re­duc­ing the rate of in­fec­tion. The

Elu­ci­da On­col­o­gy has raised an­oth­er ap­prox­i­mate­ly $30 mil­lion to bring its ver­sion of an­ti­body-drug con­ju­gates to more pa­tients in the clin­i­cal set­ting, the com­pa­ny told